相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Pharmacological Management of Postmenopausal Osteoporosis: a Level I Evidence Based-Expert Opinion
Filippo Migliorini et al.
EXPERT REVIEW OF CLINICAL PHARMACOLOGY (2021)
Relationship between P1NP, a biochemical marker of bone turnover, and bone mineral density in patients transitioned from alendronate to romosozumab or teriparatide: a post hoc analysis of the STRUCTURE trial
Junichi Takada et al.
JOURNAL OF BONE AND MINERAL METABOLISM (2020)
Denosumab or romosozumab therapy and risk of cardiovascular events in patients with primary osteoporosis: Systematic review and meta- analysis
Fang Lv et al.
BONE (2020)
Sclerostin-Antibody Treatment Decreases Fracture Rates in Axial Skeleton and Improves the Skeletal Phenotype in Growing oim/oim Mice
Mickael Cardinal et al.
CALCIFIED TISSUE INTERNATIONAL (2020)
A Randomized, Placebo-Controlled Study of Romosozumab for the Treatment of Hip Fractures
Emil H. Schemitsch et al.
JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME (2020)
Sclerostin Antibody Treatment Increases Bone Mass and Normalizes Circulating Phosphate Levels in Growing Hyp Mice
Kelsey A. Carpenter et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2020)
Osteoporosis drugs for prevention of clinical fracture in white postmenopausal women: a network meta-analysis of survival data
L. -L. Ding et al.
OSTEOPOROSIS INTERNATIONAL (2020)
Romosozumab or alendronate for fracture prevention in East Asian patients: a subanalysis of the phase III, randomized ARCH study
E. M. C. Lau et al.
OSTEOPOROSIS INTERNATIONAL (2020)
Efficacy and safety of Romosozumab in treatment for low bone mineral density: a systematic review and meta-analysis
Sara Kaveh et al.
CLINICAL RHEUMATOLOGY (2020)
Romosozumab in Skeletally Mature Adults with a Fresh Unilateral Tibial Diaphyseal Fracture A Randomized Phase-2 Study
Mohit Bhandari et al.
JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME (2020)
T-Score as an Indicator of Fracture Risk During Treatment With Romosozumab or Alendronate in the ARCH Trial
Felicia Cosman et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2020)
Serious Adverse Events With Romosozumab Use in Japanese Patients: Need for Clear Formulation of Contraindications Worldwide
Hiroshi Kawaguchi
JOURNAL OF BONE AND MINERAL RESEARCH (2020)
Explanations for the difference in rates of cardiovascular events in a trial of alendronate and romosozumab
S. R. Cummings et al.
OSTEOPOROSIS INTERNATIONAL (2020)
Low Bone Turnover Markers in Young and Middle-Aged Male Patients with Type 2 Diabetes Mellitus
X. X. Liu et al.
JOURNAL OF DIABETES RESEARCH (2020)
A single dose of zoledronate preserves bone mineral density for up to 2 years after a second course of romosozumab
M. R. McClung et al.
OSTEOPOROSIS INTERNATIONAL (2020)
Clinical efficacy and safety of drug interventions for primary and secondary prevention of osteoporotic fractures in postmenopausal women: Network meta-analysis followed by factor and cluster analysis
Fei Wen et al.
PLOS ONE (2020)
Suboptimal medication adherence may favor the progression of vertebral fractures in women with post-menopausal osteoporosis treated with denosumab
Nazarena Betella et al.
MINERVA ENDOCRINOLOGICA (2020)
Clinically Relevant Doses of Sclerostin Antibody Do Not Induce Osteonecrosis of the Jaw (ONJ) in Rats with Experimental Periodontitis
Danny Hadaya et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2019)
Sclerostin antibody reduces long bone fractures in the oim/oim model of, Check for osteogenesis imperfecta
Mickael Cardinal et al.
BONE (2019)
Bone-Forming and Antiresorptive Effects of Romosozumab in Postmenopausal Women With Osteoporosis: Bone Histomorphometry and Microcomputed Tomography Analysis After 2 and 12 Months of Treatment
Pascale Chavassieux et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2019)
Increased bone mineral density for 1year of romosozumab, vs placebo, followed by 2years of denosumab in the Japanese subgroup of the pivotal FRAME trial and extension
Akimitsu Miyauchi et al.
ARCHIVES OF OSTEOPOROSIS (2019)
Comparative efficacy of bone anabolic therapies in women with postmenopausal osteoporosis: A systematic review and network meta-analysis of randomized controlled trials
Adrian Hernandez et al.
MATURITAS (2019)
Bone mineral density gains with a second 12-month course of romosozumab therapy following placebo or denosumab
D. L. Kendler et al.
OSTEOPOROSIS INTERNATIONAL (2019)
One Year of Romosozumab Followed by Two Years of Denosumab Maintains Fracture Risk Reductions: Results of the FRAME Extension Study
E. Michael Lewiecki et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2019)
The Effect of 1 Year of Romosozumab on the Incidence of Clinical Vertebral Fractures in Postmenopausal Women With Osteoporosis: Results From the FRAME Study
Piet Geusens et al.
JBMR PLUS (2019)
Sclerostin inhibition alleviates breast cancer-induced bone metastases and muscle weakness
Eric Hesse et al.
JCI INSIGHT (2019)
Romosozumab FRAME Study: A Post Hoc Analysis of the Role of Regional Background Fracture Risk on Nonvertebral Fracture Outcome
Felicia Cosman et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2018)
Effects of 24 Months of Treatment With Romosozumab Followed by 12 Months of Denosumab or Placebo in Postmenopausal Women With Low Bone Mineral Density: A Randomized, Double-Blind, Phase 2, Parallel Group Study
Michael R. McClung et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2018)
Low Dose of Bisphosphonate Enhances Sclerostin Antibody-Induced Trabecular Bone Mass Gains in Brtl/ plus Osteogenesis Imperfecta Mouse Model
Diana Olvera et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2018)
FRAME Study: The Foundation Effect of Building Bone With 1 Year of Romosozumab Leads to Continued Lower Fracture Risk After Transition to Denosumab
Felicia Cosman et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2018)
A Phase III Randomized Placebo-Controlled Trial to Evaluate Efficacy and Safety of Romosozumab in Men With Osteoporosis
E. Michael Lewiecki et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2018)
Effects of pharmacologic sclerostin inhibition or testosterone administration on soleus muscle atrophy in rodents after spinal cord injury
Ean G. Phillips et al.
PLOS ONE (2018)
Osteocytic oxygen sensing controls bone mass through epigenetic regulation of sclerostin
Steve Stegen et al.
NATURE COMMUNICATIONS (2018)
Sclerostin Modulation Holds Promise for Dental Indications
Mohamed G. Hassan et al.
HEALTHCARE (2018)
Effects of Romosozumab Compared With Teriparatide on Bone Density and Mass at the Spine and Hip in Postmenopausal Women With Low Bone Mass
Harry K. Genant et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2017)
Romosozumab Improves Bone Mass and Strength While Maintaining Bone Quality in Ovariectomized Cynomolgus Monkeys
Michael S. Ominsky et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2017)
Primary aldosteronism as a cause of secondary osteoporosis
Antonio Stefano Salcuni et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2017)
BPS804 Anti-Sclerostin Antibody in Adults With Moderate Osteogenesis Imperfecta: Results of a Randomized Phase 2a Trial
Francis H. Glorieux et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2017)
Greater Gains in Spine and Hip Strength for Romosozumab Compared With Teriparatide in Postmenopausal Women With Low Bone Mass
Tony M. Keaveny et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2017)
Efficacy of anti-sclerostin monoclonal antibody BPS804 in adult patients with hypophosphatasia
Lothar Seefried et al.
JOURNAL OF CLINICAL INVESTIGATION (2017)
Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial
Bente L. Langdahl et al.
LANCET (2017)
Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis
Kenneth G. Saag et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Sclerostin influences body composition by regulating catabolic and anabolic metabolism in adipocytes
Soohyun P. Kim et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
Male Hypogonadism and Osteoporosis: The Effects, Clinical Consequences, and Treatment of Testosterone Deficiency in Bone Health
Gary Golds et al.
INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (2017)
Persistence with denosumab therapy in women affected by osteoporosis with fragility fractures: a multicenter observational real practice study in Italy
S. Migliaccio et al.
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION (2017)
Patients with non-ambulatory cerebral palsy have higher sclerostin levels and lower bone mineral density than patients with ambulatory cerebral palsy
Yoon-Kyum Shin et al.
BONE (2017)
Romosozumab increases bone mineral density in postmenopausal Japanese women with osteoporosis: A phase 2 study
Hideaki Ishibashi et al.
BONE (2017)
Kinetic reconstruction reveals time-dependent effects of romosozumab on bone formation and osteoblast function in vertebral cancellous and cortical bone in cynomolgus monkeys
Rogely Waite Boyce et al.
BONE (2017)
Combination sclerostin antibody and zoledronic acid treatment outperforms either treatment alone in a mouse model of osteogenesis imperfecta
David G. Little et al.
BONE (2017)
Inhibiting the osteocyte-specific protein sclerostin increases bone mass and fracture resistance in multiple myeloma
Michelle M. McDonald et al.
BLOOD (2017)
Romosozumab Treatment Converts Trabecular Rods into Trabecular Plates in Male Cynomolgus Monkeys
Jonathan B. Matheny et al.
CALCIFIED TISSUE INTERNATIONAL (2017)
Sclerostin deficiency in humans
Antoon H. van Lierop et al.
BONE (2017)
Transcriptional control of Sost in bone
Aimy Sebastian et al.
BONE (2017)
Sclerostin antibody inhibits skeletal deterioration in mice exposed to partial weight-bearing
J. M. Spatz et al.
LIFE SCIENCES IN SPACE RESEARCH (2017)
Successful induction of sclerostin in human-derived fibroblasts by 4 transcription factors and its regulation by parathyroid hormone, hypoxia, and prostaglandin E2
Makoto Fujiwara et al.
BONE (2016)
Single dose of bisphosphonate preserves gains in bone mass following cessation of sclerostin antibody in Brtl/ plus osteogenesis imperfecta model
Joseph E. Perosky et al.
BONE (2016)
Time-dependent cellular and transcriptional changes in the osteoblast lineage associated with sclerostin antibody treatment in ovariectomized rats
Scott Taylor et al.
BONE (2016)
Systemic Inflammation Affects Human Osteocyte-Specific Protein and Cytokine Expression
Janak L. Pathak et al.
CALCIFIED TISSUE INTERNATIONAL (2016)
Bone pain: current and future treatments
Charlotte Orsted Frost et al.
CURRENT OPINION IN PHARMACOLOGY (2016)
Sclerostin Expression in Bile Ducts of Patients With Chronic Cholestasis May Influence the Bone Disease in Primary Biliary Cirrhosis
Nuria Guanabens et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2016)
Sclerostin antibody (Scl-Ab) improves osteomalacia phenotype in dentin matrix protein 1(Dmp1) knockout mice with little impact on serum levels of phosphorus and FGF23
Yinshi Ren et al.
MATRIX BIOLOGY (2016)
Romosozumab Treatment in Postmenopausal Women with Osteoporosis
F. Cosman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Sclerostin inhibition promotes TNF-dependent inflammatory joint destruction
Corinna Wehmeyer et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
A bispecific antibody targeting sclerostin and DKK-1 promotes bone mass accrual and fracture repair
Monica Florio et al.
NATURE COMMUNICATIONS (2016)
Compromised vertebral structural and mechanical properties associated with progressive kidney disease and the effects of traditional pharmacological interventions
Christopher L. Newman et al.
BONE (2015)
Rapidly growing Brtl/ plus mouse model of osteogenesis imperfecta improves bone mass and strength with sclerostin antibody treatment
Benjamin P. Sinder et al.
BONE (2015)
Administration of romosozumab improves vertebral trabecular and cortical bone as assessed with quantitative computed tomography and finite element analysis
Christian Graeff et al.
BONE (2015)
Anti-Sclerostin Antibody Treatment in a Rat Model of Progressive Renal Osteodystrophy
Sharon M. Moe et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2015)
The Effect of Discontinuing Treatment With Blosozumab: Follow-up Results of a Phase 2 Randomized Clinical Trial in Postmenopausal Women With Low Bone Mineral Density
Christopher P. Recknor et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2015)
A Randomized, Double-Blind Phase 2 Clinical Trial of Blosozumab, a Sclerostin Antibody, in Postmenopausal Women with Low Bone Mineral Density
Robert R. Recker et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2015)
Effect of sclerostin antibody treatment in a mouse model of severe osteogenesis imperfecta
Andreas Roschger et al.
BONE (2014)
Progressive Increases in Bone Mass and Bone Strength in an Ovariectomized Rat Model of Osteoporosis After 26 Weeks of Treatment With a Sclerostin Antibody
Xiaodong Li et al.
ENDOCRINOLOGY (2014)
Sclerostin Deficiency Is Linked to Altered Bone Composition
Norbert Hassler et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2014)
Single-and Multiple-Dose Randomized Studies of Blosozumab, a Monoclonal Antibody Against Sclerostin, in Healthy Postmenopausal Women
Juliet McColm et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2014)
Teriparatide Increases Strength of the Peripheral Skeleton in Premenopausal Women With Idiopathic Osteoporosis: A Pilot HR-pQCT Study
Kyle K. Nishiyama et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
Multiple Doses of Sclerostin Antibody Romosozumab in Healthy Men and Postmenopausal Women With Low Bone Mass: A Randomized, Double-Blind, Placebo-Controlled Study
Desmond Padhi et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2014)
Romosozumab in Postmenopausal Women with Low Bone Mineral Density
Michael R. McClung et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Adult Brtl/+ mouse model of osteogenesis imperfecta demonstrates anabolic response to sclerostin antibody treatment with increased bone mass and strength
B. P. Sinder et al.
OSTEOPOROSIS INTERNATIONAL (2014)
Sclerostin inhibition reverses systemic, periarticular and local bone loss in arthritis
Xiao-Xiang Chen et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
Sclerostin is expressed in articular cartilage but loss or inhibition does not affect cartilage remodeling during aging or following mechanical injury
Martine Roudier et al.
ARTHRITIS AND RHEUMATISM (2013)
Sost and its paralog Sostdc1 coordinate digit number in a Gli3-dependent manner
Nicole M. Collette et al.
DEVELOPMENTAL BIOLOGY (2013)
Sclerostin Antibody Stimulates Bone Regeneration After Experimental Periodontitis
Andrei D. Taut et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2013)
Role of BMPs in the regulation of sclerostin as revealed by an epigenetic modifier of human bone cells
Jesus Delgado-Calle et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2013)
The role of estrogen and androgen receptors in bone health and disease
Stavros C. Manolagas et al.
NATURE REVIEWS ENDOCRINOLOGY (2013)
Load Regulates Bone Formation and Sclerostin Expression through a TGFβ-Dependent Mechanism
Jacqueline Nguyen et al.
PLOS ONE (2013)
Sclerostin alters serum vitamin D metabolite and fibroblast growth factor 23 concentrations and the urinary excretion of calcium
Zachary C. Ryan et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Sclerostin Inhibition Reverses Skeletal Fragility in an Lrp5-Deficient Mouse Model of OPPG Syndrome
Rajendra Kedlaya et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
Effect of sclerostin-neutralising antibody on periarticular and systemic bone in a murine model of rheumatoid arthritis: a microCT study
Massimo Marenzana et al.
ARTHRITIS RESEARCH & THERAPY (2013)
Osteoporosis in the European Union: medical management, epidemiology and economic burden
E. Hernlund et al.
ARCHIVES OF OSTEOPOROSIS (2013)
TNF-α mediates the stimulation of sclerostin expression in an estrogen-deficient condition
Beom-Jun Kim et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2012)
TGF-β regulates sclerostin expression via the ECR5 enhancer
Gabriela G. Loots et al.
BONE (2012)
Sost downregulation and local Wnt signaling are required for the osteogenic response to mechanical loading
Xiaolin Tu et al.
BONE (2012)
Targeted deletion of Sost distal enhancer increases bone formation and bone mass
Nicole M. Collette et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Sclerostin Antibody Treatment Enhances Bone Strength but Does Not Prevent Growth Retardation in Young Mice Treated With Dexamethasone
M. Marenzana et al.
ARTHRITIS AND RHEUMATISM (2011)
Increased Bone Formation and Bone Mass Induced by Sclerostin Antibody Is Not Affected by Pretreatment or Cotreatment with Alendronate in Osteopenic, Ovariectomized Rats
Xiaodong Li et al.
ENDOCRINOLOGY (2011)
Bone Overgrowth-associated Mutations in the LRP4 Gene Impair Sclerostin Facilitator Function
Olivier Leupin et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
Single-Dose, Placebo-Controlled, Randomized Study of AMG 785, a Sclerostin Monoclonal Antibody
Desmond Padhi et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2011)
Increased chondrocyte sclerostin may protect against cartilage degradation in osteoarthritis
B. Y. Chan et al.
OSTEOARTHRITIS AND CARTILAGE (2011)
The Appearance and Modulation of Osteocyte Marker Expression during Calcification of Vascular Smooth Muscle Cells
Dongxing Zhu et al.
PLOS ONE (2011)
Sclerostin Stimulates Osteocyte Support of Osteoclast Activity by a RANKL-Dependent Pathway
Asiri R. Wijenayaka et al.
PLOS ONE (2011)
Wnt Antagonists Bind through a Short Peptide to the First β-Propeller Domain of LRP5/6
Eric Bourhis et al.
STRUCTURE (2011)
Sclerostin is a direct target of osteoblast-specific transcription factor osterix
Fan Yang et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2010)
Distinct Modes of Inhibition by Sclerostin on Bone Morphogenetic Protein and Wnt Signaling Pathways
Carola Krause et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Wnt Inhibitors Dkk1 and Sost Are Downstream Targets of BMP Signaling Through the Type IA Receptor (BMPRIA) in Osteoblasts
Nobuhiro Kamiya et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2010)
Parathyroid Hormone (PTH)-Induced Bone Gain Is Blunted in SOST Overexpressing and Deficient Mice
Ina Kramer et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2010)
Two Doses of Sclerostin Antibody in Cynomolgus Monkeys Increases Bone Formation, Bone Mineral Density, and Bone Strength
Michael S. Ominsky et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2010)
Inhibition of Sclerostin by Monoclonal Antibody Increases Bone Formation, Bone Mass, and Bone Strength in Aged Male Rats
Xiaodong Li et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2010)
Hypoxia Decreases Sclerostin Expression and Increases Wnt Signaling in Osteoblasts
Damian C. Genetos et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2010)
Skeletal Health: Primate Model of Postmenopausal Osteoporosis
S. Y. Smith et al.
AMERICAN JOURNAL OF PRIMATOLOGY (2009)
Pro-Inflammatory Cytokines TNF-Related Weak Inducer of Apoptosis (TWEAK) and TNFα Induce the Mitogen-Activated Protein Kinase (MAPK)-Dependent Expression of Sclerostin in Human Osteoblasts
Cristina Vincent et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2009)
Sclerostin Mediates Bone Response to Mechanical Unloading Through Antagonizing Wnt/β-Catenin Signaling
Chuwen Lin et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2009)
Sclerostin Antibody Treatment Increases Bone Formation, Bone Mass, and Bone Strength in a Rat Model of Postmenopausal Osteoporosis
Xiaodong Li et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2009)
Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength
Xiaodong Li et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2008)
Mechanical stimulation of bone in vivo reduces osteocyte expression of Sost/sclerostin
Alexander G. Robling et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
SOST expression is restricted to the great arteries during embryonic and neonatal cardiovascular development
Rutger L. van Bezooijen et al.
DEVELOPMENTAL DYNAMICS (2007)
Bone density ligand, sclerostin, directly interacts with LRP5 but not LRP5G171V to modulate Wnt activity
Debra L. Ellies et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2006)
SOST is a target gene for PTH in bone
H Keller et al.
BONE (2005)
SOST is a ligand for LRP5/LRP6 and a Wnt signaling inhibitor
M Semënov et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease
GG Loots et al.
GENOME RESEARCH (2005)
Sclerostin inhibition of Wnt-3a-induced C3H10T1/2 cell differentiation is indirect and mediated by bone morphogenetic proteins
DG Winkler et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Cbfa1/RUNX2 directs specific expression of the sclerosteosis gene (SOST)
B Sevetson et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Sclerostin promotes the apoptosis of human osteoblastic cells: a novel regulation of bone formation
MK Sutherland et al.
BONE (2004)
Osteocyte control of bone formation via sclerostin, a novel BMP antagonist
DG Winkler et al.
EMBO JOURNAL (2003)
Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease
W Balemans et al.
JOURNAL OF MEDICAL GENETICS (2002)
Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein
ME Brunkow et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2001)
Risk of new vertebral fracture in the year following a fracture
R Lindsay et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2001)
分享论文
